A speedy new scan could improve how millions of people with high blood pressure are treated, suggests a new study led by UCL (University College London) researchers.
Hay fever, also known as allergic rhinitis, is the condition responsible for seasonal allergies or allergic reactions to other environmental allergens, like dust mites and animal dander. Ultimately, these symptoms disrupt daily activities and affect quality of life for hay fever sufferers.
New computer modeling could help scientists better understand how the retina regenerates, opening the door to new treatments for vision loss, according to a study from the University of Surrey.
The precise identification of tumor boundaries during radical prostatectomy remains a major clinical challenge. As positive surgical margins occur in 15–40% of prostate cancer cases, the risk of postoperative recurrence and functional impairment is significantly increased.
Researchers have created an artificial intelligence model that can identify which mutations in human proteins are most likely to cause disease, even when those mutations have never been seen before in any person.
Patients with the deadliest form of brain cancer, glioblastoma, who received MRI-guided focused ultrasound with standard-of-care chemotherapy had a nearly 40% increase in overall survival in a landmark trial of 34 patients led by University of Maryland School of Medicine (UMSOM) researchers.
CeriBell (Nasdaq:CBLL) announced today that it received FDA 510(k) clearance for its next-generation Clarity algorithm.
Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers.
A new study has shown that a clinical tool developed by the University of Liverpool and The Walton Center can accurately predict whether the most common type of brain tumor will grow or cause symptoms, helping doctors and patients make better-informed decisions about care.
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.